RecruitingNCT07701161
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
Sponsor
Neurogen Biomarking LLC
Enrollment
1,000 participants
Start Date
Jan 13, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
Eligibility
Min Age: 40 YearsMax Age: 90 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with alzheimer s disease, biomarkers, and other related conditions. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 40 Years to 90 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07701161
Related Trials
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
NCT0721472713 locations
Dominantly Inherited Alzheimer Network (DIAN)
NCT0086981726 locations
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203126 locations
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT0546210626 locations